Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AACAP: Attenade Offers Longer Duration Of Action Than Ritalin WARREN, N.J. -- October 25, 1999 -- Complete analysis of the two pivotal efficacy trials for Celgene Corporation’s Attenade™ (d-methylphenidate), found that the drug met all efficacy parameters for controlling the symptoms of attention deficit disorder (ADD) and attention deficit hyperactivity (ADHD) in school age children. Attenade is the chirally pure version of Ritalin® (dl-methylphenidate). The results were presented by James Swanson, Ph.D., professor of pediatrics, psychiatry, and social sciences at the University of California-Irvine at the annual meeting of the American Academy of Child and Adolescent Psychiatry in Chicago. More than 200 children participated in the multi-center trials. Both trials compared Attenade to placebo; the second trial directly compared the efficacy of both Attenade and Ritalin to placebo. The trial comparing Attenade and Ritalin demonstrated a statistically significant longer duration of action for Attenade. Attenade controlled the symptoms of ADD/ADHD at all times measured in the study while dl-methylphenidate did not control the symptoms at the last measurements (5.5 to 6.5 hours after study dosing). In both trials, behavioral and objective measures were examined. Attenade had favorable scores over dl-methylphenidate in all parameters measured. The results of the primary efficacy analysis indicated that Attenade was significantly more effective than placebo (p=0.0003) as evaluated by a behavioral scale (Teacher SNAP-ADD/ADHD), signifying an improvement in the clinical status of the children. The results of the second trial confirmed the drug’s efficacy, and it demonstrated a significant longer duration of action for Attenade versus Ritalin (p=0.015) as measured by a behavioral scale. "The results strongly confirmed the earlier Phase I/II trial protocol, which evaluated patients in a ‘model classroom’ setting and suggested the control afforded by Attenade for ADD/ADHD symptoms," said Dr. Swanson, who is also the director of the UC-Irvine Child Development Center. The Journal of the American Medical Association has reported that three to six percent of school-age children (elementary to high school) have ADD/ADHD. The condition is characterized by symptoms of inappropriate inattention, hyperactivity and impulsiveness. It estimated that between one and two million children in the U.S. are now being treated for this condition. North American sales of drugs treating these symptoms are estimated to exceed $500 million per year. "Celgene will incorporate this important data in our New Drug Application (NDA) submission for Attenade, which we expect to be completed in the first half of next year," said Sol Barer, Ph.D., President and COO of Celgene. "The company also plans to initiate new clinical trials to assess several critical medical and commercial opportunities for Attenade, including the potential for a single-dose regimen to control ADD/ADHD symptoms for a typical school day. We will also assess whether at the end of the day when many children get highly agitated as the drug wears off-i.e., the rebound effect-occurs as often and with as much intensity as the currently commercialized racemic form of methylphenidate." Celgene will also evaluate the potential of Attenade to treat the underserved, and commercially substantial, adult ADD/ADHD market, using a less-frequent dosing schedule than is currently employed with other psycho-stimulants including dl-methylphenidate (Ritalin)," said Jerome Zeldis, MD, Ph.D., Vice President of Medical Affairs at Celgene. Development of the proprietary pulse-release formulation will also proceed, he noted. "We are very encouraged by the completed analysis of these pivotal trials, and are optimistic Attenade can be an important addition to the ADD/ADHD treatment armamentarium," said Dr. Barer. The incidence of side effects in the trials was very low. Compared to placebo, both Attenade and dl-methylphenidate were associated with decreased appetite and mild abdominal pain. Full evaluation of the safety profile awaits completion of on-going trials early next year. Celgene holds five patents covering the use and manufacture of d-methylphenidate (Ritalin) as both immediate and pulse release formulations. Related Links: Celgene Corporation and Ritalin. E-mail this page to a friend or colleague! To print, use this version